Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.

Published byStella Barker Modified over 6 years ago

Similar presentations

Presentation on theme: "Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance."— Presentation transcript:

1 Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance (NGT) or (B) type 2 diabetes mellitus (T2DM). Plasma glucose profiles of oral glucose tolerance test (OGTTs) (filled symbol) and IIGI studies (open symbol) in subjects with (C) NGT or (D) T2DM. Adapted from Oh et al. [21], with permission from John Wiley and Sons. Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance (NGT) or (B) type 2 diabetes mellitus (T2DM). Plasma glucose profiles of oral glucose tolerance test (OGTTs) (filled symbol) and IIGI studies (open symbol) in subjects with (C) NGT or (D) T2DM. Adapted from Oh et al. [21]. . . Endocrinol Metab Mar;31(1):

Download ppt "Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance."

Similar presentations

Hyperglycemia and Acute Coronary Syndromes. Cardiovascular disease and diabetes Bell DSH. Diabetes Care. 2003;26:2433-41. Centers for Disease Control.

Hyperglycemia and Acute Coronary Syndromes. Cardiovascular disease and diabetes Bell DSH. Diabetes Care. 2003;26: Centers for Disease Control.
GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.
Beta Cell Mass in Type 2 DM Gepts et al McClean et al Westermark et al Saito et al Stefan et al Ann Roy Sci Med Nat 10:1, 1957 Reduced Diabetes 4:367,

Beta Cell Mass in Type 2 DM Gepts et al McClean et al Westermark et al Saito et al Stefan et al Ann Roy Sci Med Nat 10:1, 1957 Reduced Diabetes 4:367,
Part 4.

Part 4.
Part 5. Insulin Resistance and  -Cell Dysfunction: Summary Individuals with impaired glucose tolerance –Are maximally or near-maximally insulin resistant.

Part 5. Insulin Resistance and  -Cell Dysfunction: Summary Individuals with impaired glucose tolerance –Are maximally or near-maximally insulin resistant.
Anesthes. 2008;108(3): doi: /ALN.0b013e Figure Legend:

Anesthes. 2008;108(3): doi: /ALN.0b013e Figure Legend:
Infusion of Hi-Xen reduces the iAUCs for gastric emptying and postprandial glucose levels in humans with NGT, IGT, and T2DM. Infusion of Hi-Xen reduces.

Infusion of Hi-Xen reduces the iAUCs for gastric emptying and postprandial glucose levels in humans with NGT, IGT, and T2DM. Infusion of Hi-Xen reduces.
Fig. 1. Time line for investigations

Fig. 1. Time line for investigations
Glucose tolerance testing. A

Glucose tolerance testing. A
Copyright © 2017 American Academy of Pediatrics.

Copyright © 2017 American Academy of Pediatrics.
The oral glucose tolerance test (OGTT) revisited

The oral glucose tolerance test (OGTT) revisited
The relationship of angiographically defined coronary artery disease with insulin sensitivity and secretion in subjects with different glucose tolerance 

The relationship of angiographically defined coronary artery disease with insulin sensitivity and secretion in subjects with different glucose tolerance 
Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo
Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.
Diabetes and Pregnancy

Diabetes and Pregnancy
Fig. 3. Plasma profiles of active GIP (A) and total GIP (B) concentrations after administration of single oral doses of sitagliptin 25 (white circles)

Fig. 3. Plasma profiles of active GIP (A) and total GIP (B) concentrations after administration of single oral doses of sitagliptin 25 (white circles)
Figure 1. Correlations between TNFα and HOMA IR in men (•) and women (○). Circulating Tumor Necrosis Factor-α Concentrations in a Native Canadian Population.

Figure 1. Correlations between TNFα and HOMA IR in men (•) and women (○). Circulating Tumor Necrosis Factor-α Concentrations in a Native Canadian Population.
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 2 Pathophysiology of hyperglycaemia in T2DM

Figure 2 Pathophysiology of hyperglycaemia in T2DM
with undiagnosed diabetes mellitus by three diagnostic criteria

with undiagnosed diabetes mellitus by three diagnostic criteria

Similar presentations

Ads by Google